Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Observational 1

Sponsor

Cancer Type

Other 1

Conditions

Smoking 1Pulmonary Disease, Chronic Obstructive 1Overweight 1Obesity 1Noncommunicable Diseases 1Neoplasms 1Hypokinesia 1Hypertension 1Hyperglycemia 1Dyslipidemias 1Diabetes Mellitus 1Coronary Disease 1Cerebrovascular Disorders 1Breast Neoplasms 1Asthma 1Alcohol Drinking 1

Interventions

Drug Therapy 4pembrolizumab 3Thermography 2Surveys and Questionnaires 2Standard of Care 2Quality of Life 2Preoperative Exercise 2Nivolumab 2Moxibustion 2Hematologic Tests 2Cyclophosphamide 2Chemoradiotherapy 2vandetanib 1sinovac COVID-19 vaccine 1lenvatinib 1ibrutinib 1fludarabine 1encorafenib 1durvalumab 1binimetinib 1beta Carotene 1avelumab 1atezolizumab 1Zoledronic Acid 1Zinc 1Vitamin E 1Vascular Access Devices 1Validation Studies as Topic 1Urination 1Ultraviolet Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Neoplasms × Electrocardiography × Clear all
NCT06812767 2025-02-06

FORTUNE

National Medical Research Center for Therapy and Preventive Medicine

Enrolling by invitation
2,000 enrolled
Other

Noncommunicable Diseases, Alcohol Drinking, Asthma, Cerebrovascular Disorders, Coronary Disease, Diabetes Mellitus, Hyperglycemia, Hypertension, Neoplasms, Obesity, Smoking, Hypokinesia, Pulmonary Disease, Chronic Obstructive, Dyslipidemias, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡